Clinical Trial

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

Study acronym: Combi G-Vax
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for glioblastoma and then treated with standard radiochemotherapy (according to Stupp regimen).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-08-19; most recent amendment 2025-07-17.
Status change: Not Yet Recruiting → Recruiting 2023-02-15
Trial Details
NCT Number NCT04523688
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Glioblastoma, Vaccination
Enrollment 28 participants
Start Date 2021-03-25
Primary Completion 2025-07 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-22